PT  - JOURNAL ARTICLE
AU  - Hamblin, Rachelle
AU  - Lee, Victoria T.
AU  - deGuzman, Brian J.
AU  - Verma, Suman
AU  - Aklog, Lishan
TI  - Clinical Utility of EsoGuard® as a Triage Test for Endoscopy to Identify Barrett’s Esophagus in Fire Fighters
AID  - 10.1101/2023.08.16.23294176
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.16.23294176
4099  - http://medrxiv.org/content/early/2023/08/29/2023.08.16.23294176.short
4100  - http://medrxiv.org/content/early/2023/08/29/2023.08.16.23294176.full
AB  - Background Firefighters have frequent exposure to smoke and compounds that have been shown to increase the risk of developing esophageal neoplasia. EsoGuard® is a DNA biomarker assay that can be utilized with efficiency and high tolerability as a triage test in the diagnosis of patients with Barrett’s Esophagus (BE) and/or esophageal adenocarcinoma (EAC) in this population.Methods This is a retrospective analysis of prospectively collected clinical utility data on use of EsoGuard® DNA testing on samples collected with the nonendoscopic esophageal cell collection device, EsoCheck®, during two large cancer screening events for firefighters in San Antonio, TX, in January 2023.Results A total of 388 firefighters volunteered for screening of Barrett’s Esophagus and esophageal adenocarcinoma, of which 385 (>99%) successfully provided cell samples for EsoGuard analysis. There was a 7.27% (28/385) positivity rate, which was similar among males and females (7.26% and 7.41%, respectively). Only 13/385 (3.37%) tests failed analysis due to insufficient DNA sampling. Among those who tested positive with EsoGuard, 100% (28/28) were referred by the ordering physician for gastroenterology and upper endoscopy evaluation. Among those who tested negative, none were referred for upper endoscopy evaluation. This resulted in a 100% concordance between EsoGuard results and physician management decisions.Conclusions This study capturing real-world data on the use of EsoGuard for early detection of BE/EAC in firefighters demonstrates the ability of this diagnostic tool to efficiently screen high-risk populations in a manner that is well tolerated, has high result yield, and effectively drives physician management decisions.Competing Interest StatementR.H. declares no conflict of interest. V.T.L., B.J.D., and L.A., are executive members of PAVmed Inc., of which Lucid Diagnostics Inc. is a subsidiary, and owns stock and/or options in the parent company. S.V. is an executive member of Lucid Diagnostics Inc. and owns stock and/or options in the company. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:On March 6, 2023, WCG IRB approved a request for a waiver of authorization for use and disclosure of protected health information (PHI) for the above-referenced research. This review was conducted through expedited review. Please note that this letter is supplemental to the WCG IRB Certificate of Action for this study. WCG IRB determined that documentation received from you satisfies the three requirements for a waiver of authorization under 45 CFR 164.512. These requirements are: 1.The use or disclosure of the PHI involves no more than minimal risk to the individuals, based on the following elements: a.An adequate plan to protect identifiers from improper use and disclosure; b.An adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research (unless there is a health or research justification for retaining the identifiers, or such retention is otherwise required by law); and, c.Adequate written assurances that the PHI will not be reused or redisclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of PHI would be permitted by HIPAA. 2.The research could not be practicably conducted without access to and use of the PHI; and, 3.The research could not practicably be conducted without the waiver. The Board has determined that this waiver of authorization for the use and access of the protected health information as described in the above referenced protocol, and in the information provided in the submitted waiver of authorization form, is necessary for conduct of this research. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors